Cortagen and Epitalon Interaction: Synergistic | Peptide Database

YK-11's dual mechanism of AR agonism and myostatin inhibition theoretically positions it as a potent anabolic compound for increasing lean muscle mass. Cell culture data supports increased anabolic signaling and follistatin expression. However, there is no in vivo or clinical evidence confirming these effects in animals or humans. All efficacy reports are anecdotal. Users anecdotally report significant strength gains during YK-11 cycles, consistent with the compound's theoretical mechanism of action. The combination of AR-mediated protein synthesis and myostatin inhibition could theoretically support enhanced force production. No controlled studies exist to verify these claims. The most distinctive proposed benefit of YK-11 is its ability to upregulate follistatin and thereby inhibit myostatin-mediated limitations on muscle growth. In cell culture, YK-11 induced greater follistatin expression than DHT. If this translates to in vivo activity, it could allow muscle growth beyond normal physiological limits. This remains entirely unproven outside of cell-based assays. Follistatin has been shown in other research contexts to positively influence bone mineral density and bone formation. If YK-11's follistatin-inducing effects translate in vivo, there could be secondary benefits for bone density. This is entirely speculative and unsupported by any direct YK-11 bone data.

Join others researching Tamoxifen — share findings, ask questions, and learn from real experiences Tamoxifen is a first-generation selective estrogen receptor modulator (SERM) that has been in clinical use since the 1970s. It is FDA-approved for the treatment and prevention of estrogen receptor-positive breast cancer and remains one of the most widely prescribed cancer therapies worldwide. In the context of performance enhancement, tamoxifen is used extensively for post-cycle therapy (PCT) to restore the hypothalamic-pituitary-testicular axis after suppression from anabolic steroids, and for on-cycle gynecomastia prevention by blocking estrogen receptors in breast tissue. Tamoxifen acts as an estrogen antagonist in breast and hypothalamic tissue while functioning as a partial estrogen agonist in bone, the uterus, and the cardiovascular system. Its active metabolite endoxifen, produced via CYP2D6 metabolism, is responsible for much of its pharmacological activity. Tamoxifen competitively binds to estrogen receptors (primarily ERalpha) and exerts tissue-selective effects depending on the local coactivator and corepressor environment. In breast tissue and the hypothalamus, tamoxifen acts as an estrogen antagonist, blocking estradiol-mediated signaling. At the hypothalamus and anterior pituitary, this antagonism removes estrogen-driven negative feedback on GnRH secretion, leading to increased pulsatile GnRH release and subsequent elevation of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The rise in LH stimulates Leydig cell testosterone production, which is the basis for its use in post-cycle therapy. In bone tissue, tamoxifen acts as a partial estrogen agonist, providing a protective effect on bone mineral density. Tamoxifen is a prodrug that requires hepatic metabolism via CYP3A4 and CYP2D6 to generate its active metabolites, particularly endoxifen, which has approximately 100-fold greater affinity for the estrogen receptor than the parent compound.